Thank you for attending!

Thank you for attending the independent CME symposium, “Individualized Care in the Era of Immuno-Oncology: Focus on Bladder and Renal Cancers,” on 17 March, 2019, at the European Association of Urology 2019 (EAU19) Annual Meeting in Barcelona, Spain. 

To claim your CME certificate, please email us (cme@cme-cpd.org) and we'll send you to the CME portal to complete a brief survey. Let us know if you'd like a copy of the symposium slides, and we are happy to share those with you. 

Download the IO Toxicity Tool

The EIOCC IO Toxicity Tool integrates guideline recommendations on the management of immune-related adverse events from the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), and Society for Immunotherapy of Cancer (SITC).  

Faculty

Rajesh Nair, Chair Guy’s and St. Thomas’ NHS Foundation Trust London, UK		Maria Carmen Mir Maresma Instituto Valenciano de Oncología     Valencia, Spain		Mario W. Kramer Universitätsklinikum Schleswig-Holstein Lübeck, Germany

Overview

Immune checkpoint inhibitors play a key role in medical management of select patients with urologic cancers. Using interactive case discussions, this session will focus on the rationale for targeting the immune checkpoint pathway in bladder and renal cancers; the role of biomarkers such as programmed death-ligand 1 (PD-L1) and tumor mutation burden (TMB) to guide the selection of appropriate first- and subsequent-line therapy; the use of immune-specific response criteria to monitor treatment response; and options for managing immune-related adverse events during treatment.

Learning objectives

• Evaluate the rationale for targeting immune checkpoint molecules in bladder and renal cancers
• Apply the latest clinical evidence to the selection and sequencing of immuno-oncology (IO) therapies in patients with bladder and renal cancers
• Select appropriate strategies to assess treatment response and mitigate adverse events during IO therapy

Agenda

Sunday, 17 March 2019 | Green Room 1

17:45 – 17:50

Welcome and introduction

R. Nair, London (UK)

17:50 – 18:15

Checkpoint inhibitors in urologic cancers: where are we and where are we going?

M.C. Mir Maresma, Valencia (ES)

M.W. Kramer, Lübeck (DE)

18:15 – 18:40

Case 1: patient with advanced renal cancer

M.C. Mir Maresma, Valencia (ES)

18:40 – 19:05

Case 2: patient with newly diagnosed bladder cancer

M.W. Kramer, Lübeck (DE)

19:05 – 19:15

Q & A and closing remarks

R. Nair, London (UK)

CME information

Siyemi Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Siyemi Learning designates this activity for 1.5 AMA PRA Category 1 credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Disclosure statement

Siyemi Learning, as an organisation accredited by the ACCME, requires everyone involved in this CME activity to disclose all relevant financial relationships. This is defined as a financial relationship (including that of a spouse or partner), in any amount, occurring in the past 12 months, that could lead to potential bias.

Mario W. Kramer has served as an advisor for: BMS, Pfizer, Pierre Fabre, MSD and Roche.

Rajesh Nair and M. Carmen Mir Maresma have no relevant financial relationships to disclose.

Staff at Siyemi Learning have no relevant financial relationships to disclose.

Commercial support

This educational activity is supported by an independent education grant from MSD.